Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

SOHO 2022 | Promising agents under investigation for the treatment of myelofibrosis with cytopenia

Jeanne Palmer • 29 Sep 2022
SOHO 2022
Myelofibrosis Myeloproliferative Neoplasms Danazol Luspatercept Momelotinib Pacritinib
MOMENTUM

In this video, Jeanne Palmer, MD, Mayo Clinic, Phoenix, AZ, gives an overview of promising agents being investigated for the treatment of myelofibrosis (MF) with cytopenia, including pacritinib, momelotinib, and luspatercept. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jeanne Palmer

Investigating the place of JAK inhibitors in the treatment of myelofibrosis 0:53
Investigating the place of JAK inhibitors in the treatment of myelofibrosis
Jeanne Palmer • 29 Sep 2022
Strategies to improve the quality of life of patients with MPNs 1:12
Strategies to improve the quality of life of patients with MPNs
Jeanne Palmer • 29 Sep 2022
Understanding the impact of therapies on treatment-emergent mutations in MF to prevent progression 1:12
Understanding the impact of therapies on treatment-emergent mutations in MF to prevent progression
Jeanne Palmer • 29 Sep 2022
The role of allogeneic transplant in myelofibrosis and important factors to consider 3:36
The role of allogeneic transplant in myelofibrosis and important factors to consider
Jeanne Palmer • 27 Aug 2022

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals